|
|
|
Volumn 43, Issue 1106, 2001, Pages 49-50
|
|
Gleevec (STI-571) for chronic myeloid leukemia
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYTARABINE;
ERYTHROMYCIN;
IMATINIB;
ITRACONAZOLE;
PHENYTOIN;
PROTEIN TYROSINE KINASE INHIBITOR;
RECOMBINANT ALPHA2A INTERFERON;
RECOMBINANT ALPHA2B INTERFERON;
UNCLASSIFIED DRUG;
WARFARIN;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG ABSORPTION;
DRUG COST;
DRUG ELIMINATION;
DRUG INDICATION;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG PROTEIN BINDING;
HUMAN;
SARCOMA;
SHORT SURVEY;
SIDE EFFECT;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FEES, PHARMACEUTICAL;
GASTROINTESTINAL NEOPLASMS;
HUMANS;
LEUKEMIA, MYELOID, CHRONIC;
PIPERAZINES;
PYRIMIDINES;
|
|
EID: 0035844320
PISSN: 0025732X
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
|
Times cited : (8)
|
|
References (0)
|